These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 15258963

  • 1. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V.
    J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
    [Abstract] [Full Text] [Related]

  • 2. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D, ANRS Resistance Study Group.
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [Abstract] [Full Text] [Related]

  • 3. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [Abstract] [Full Text] [Related]

  • 4. Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
    Bogner JR, Eberle J, Troendle U, Goebel FD.
    Eur J Med Res; 2003 Feb 21; 8(2):49-55. PubMed ID: 12626281
    [Abstract] [Full Text] [Related]

  • 5. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Murphy MD, Marousek GI, Chou S.
    J Clin Virol; 2004 May 21; 30(1):62-7. PubMed ID: 15072756
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P.
    HIV Med; 2004 Jul 21; 5(4):284-8. PubMed ID: 15236618
    [Abstract] [Full Text] [Related]

  • 7. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H, King MS, King K, Molla A, Brun S, Kempf DJ.
    J Virol; 2005 Mar 21; 79(6):3329-38. PubMed ID: 15731227
    [Abstract] [Full Text] [Related]

  • 8. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 21; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 9. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA, ESS40011 (STARR) Study Team.
    BMC Infect Dis; 2003 Jun 10; 3():10. PubMed ID: 12795812
    [Abstract] [Full Text] [Related]

  • 10. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.
    Antivir Ther; 2002 Sep 10; 7(3):165-74. PubMed ID: 12487383
    [Abstract] [Full Text] [Related]

  • 11. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
    Santos JR, Llibre JM, Imaz A, Domingo P, Iribarren JA, Mariño A, Miralles C, Galindo MJ, Ornelas A, Moreno S, Schapiro JM, Clotet B, Call Conference Group.
    J Antimicrob Chemother; 2012 Jun 10; 67(6):1462-9. PubMed ID: 22431669
    [Abstract] [Full Text] [Related]

  • 12. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C, Pérez-Elías MJ, Delgado R, Ruiz L, Nájera R, Pumarola T, Alonso-Socas Mdel M, García-Bujalance S, Menéndez-Arias L, Spanish Group for the Study of Antiretroviral Drug Resistance.
    J Med Virol; 2007 Nov 10; 79(11):1617-28. PubMed ID: 17854027
    [Abstract] [Full Text] [Related]

  • 13. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov 10; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 14. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA, Wilkins E, Murphy M, Fisher M, de Ruiter A, Easterbrook PJ, Leen C, Vlahakis E, Cane PA, Li X, Pillay D, UK Expanded Access Amprenavir Programme.
    Antivir Ther; 2003 Aug 10; 8(4):301-8. PubMed ID: 14518699
    [Abstract] [Full Text] [Related]

  • 15. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
    Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vézinet F.
    J Antimicrob Chemother; 2009 Mar 10; 63(3):585-92. PubMed ID: 19147519
    [Abstract] [Full Text] [Related]

  • 16. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA, Arduino RC.
    Expert Rev Anti Infect Ther; 2007 Jun 10; 5(3):349-63. PubMed ID: 17547501
    [Abstract] [Full Text] [Related]

  • 17. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 10; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 18. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L, de Mendoza C, Soriano V.
    J Med Virol; 2005 Dec 10; 77(4):460-4. PubMed ID: 16254964
    [Abstract] [Full Text] [Related]

  • 19. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Lazzarin A, Castagna A.
    J Med Virol; 2006 Dec 10; 78(12):1537-41. PubMed ID: 17063520
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.